Altimmune
Gaithersburg, Maryland, United States · Biopharma, Biotechnology, Health Care
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obe
Key facts
- Headquarters
- Gaithersburg, Maryland, United States
- Employees
- 59
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (ALT)
- Website
- altimmune.com
- Company page
Recent activity at Altimmune
- : Altimmune Appoints Richard Menziuso as Vice President, Global Controller
- : SEC 8-K (5.02): On September 24, 2026, Altimmune, Inc. appointed Richard Menziuso as the Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Mr. Menziuso brings 28 years of finance and accounting experience, notably serving as Vice President, Corporate Controller at Centessa Pharmaceuticals until its recent acquisition by Eli Lilly. His appointment is expected to enhance the financial leadership of Altimmune as they continue to advance in the biopharmaceutical sector. Gregory Weaver will maintain his position as the Chief Financial Officer, ensuring continuity in the company's financial strategy during this transition.
- : SEC 8-K (8.01): On June 16, 2026, Altimmune, Inc. announced plans to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey later this year. The new headquarters is strategically located in an area with a strong presence of biopharmaceutical companies, which is anticipated to enhance the Company’s ability to attract top-tier talent. The Company has entered into a 5-year office lease agreement, committing to annual rent payments of approximately $300,000. This move is expected to help Altimmune achieve cost efficiencies and support its growth as a late-stage development company.
- : SEC 8-K (1.01): On November 5, 2025, Altimmune, Inc. entered into an amendment to its Loan and Security Agreement with Hercules Capital, Inc. and associated lenders, which increased the total available term loan from $100.0 million to $125.0 million. This amendment modifies the existing agreement dated May 13, 2025, allowing for up to four tranches of borrowing, with conditions attached. The first tranche of $15.0 million was drawn down on the original agreement's closing date. This financial arrangement is expected to provide Altimmune with increased liquidity to support its operational and strategic goals.
- : Altimmune Appoints Linda M. Richardson as Chief Commercial Officer
- : Altimmune, Inc. Presents New Data on Pemvidutide's Effects on Inflammatory Lipids for Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting® 2024.
- : Altimmune Appoints Greg Weaver as Chief Financial Officer
Leadership
- Richard Menziuso, Vice President
- Laura Gibbs, Chief Operating Officer
- M. Scott Harris, Chief Executive Officer
- Lisa Simpson-Smith, Hr Professional
- Andrew Shutterly, Experienced and Effective Accountant
- Aklilu Meshesha, Director of Financial Reporting
- Kent Tapper, Recently Retired
- Vyjayanthi Krishnan, Technical Lead On Pd Studies
- Bertrand Georges, Chief Technology Officer
- Sarah Browne, Not Specified In the Text
- Audrey Sykes, Experience In Life Science and Diagnostics
- Siavoche Siassi, Life Sciences Strategy and Marketing Professional
Verified email and direct lines for Altimmune’s decision-makers are on Fundz. See plans
Employee benefit plans
Altimmune files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Altimmune in the news
- Altimmune to Participate in Stifel Cardiometabolic Forum - Yahoo Finance (Sep 23, 2026)
- Press Release of Altimmune, Inc. dated May 13, 2026 - SEC.gov - SEC.gov (May 13, 2026)
- Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win - Fierce Biotech (Jul 28, 2026)
- Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow (NASDAQ:ALT) 2026-07-28 - Seeking Alpha (Jul 28, 2026)
- Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Yahoo Finance (Jul 28, 2026)
- Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals (Apr 27, 2026)
- Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third quarter 2026 - SEC.gov (Mar 05, 2026)
- Altimmune Announces Second Quarter 2026 Financial Results and Business Update - The Manila Times (Aug 12, 2026)
Companies similar to Altimmune
- Takis S.r.l · Biopharma, Biotechnology, Health Care, research, Therapeutics
- BioLineRx Ltd · Biopharma, Biotechnology, Health Care, research, Therapeutics
- Cantargia AB · Biopharma, Biotechnology, Health Care, research, Therapeutics
- Applied StemCell · Biotechnology, Health Care, research, Therapeutics
- Zai Lab Limited & MediLink Therapeutics (Suzhou) Ltd · Biopharma, Biotechnology, Health Care, Therapeutics
About Altimmune: questions and answers
What does Altimmune do?
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obe
Where is Altimmune headquartered?
Altimmune is headquartered in Gaithersburg, Maryland, United States.
How many employees does Altimmune have?
Altimmune has about 59 employees.
Who leads Altimmune?
Richard Menziuso is a Vice President at Altimmune.
What is the latest news on Altimmune?
On Sep 29, 2026, Altimmune Appoints Richard Menziuso as Vice President, Global Controller
Is Altimmune a public company?
Yes. Altimmune is publicly traded under the ticker ALT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy